- AbbVie recorded $847 million intangible asset impairment for Resonic and Durysta.
- Acquisition and integration costs primarily relate to the Capstan acquisition.
AbbVie reported an $847 million intangible asset impairment charge tied to Resonic and Durysta. The adjusted tax rate for the first nine months of 2025 was 17.9%.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.